<a href="https://www.nanowerk.com/nanotechnology-news/newsid=43724.php" target="_blank">Collaboration with pharma will introduce nanotechnologies in early stage drug development</a>&nbsp;&nbsp;<font color="#6f6f6f">Nanowerk</font>

Collaboration with pharma will introduce nanotechnologies in early stage drug development - Nanowerk

University of Maryland

Director of Drug Product Development at Applied Biological Laboratories Inc.

Walter Reed Army Institute of Research

Business Development Manager, Pilot Bioproduction Facility (PBF)

Applied Biological Laboratories Inc. is a New York biotechnology company committed to the research, development, manufacturing, and distribution of scientifically validated natural products that strengthen the body’s innate defenses. Our first round of products contain powerful molecules identified in our laboratories as well as through decades of peer-reviewed scientific research at leading universities to have profound affects in protecting against and recovering from some of the most common respiratory ailments.

Applied Biological Laboratories Inc.

Director of Drug Product Development

The Vaccine Translational Research Branch (VTRB) oversees the development of a portfolio of investigational products, including antibodies for HIV treatment and prevention and HIV vaccine products incorporating nanoparticles, peptide and protein immunogens, DNA, RNA, and adjuvants.

In VTRB, Jennifer manages product development of anti-HIV antibodies, and has experience with the entire lifecycle for these products - including cell line development, upstream/downstream process development, development of analytics, preclinical IND-enabling studies, CMC preparation, into clinical trials. She also provides nanotechnology expertise and strategies for investigational vaccines incorporating nanoparticles, including cell based and synthetic vaccines, and nanoparticles for mRNA delivery.

National Institute of Allergy and Infectious Diseases (NIAID)

Senior Scientific Program Manager

Hood College

Adjunct Professor, Chemistry & Physics

American University

Adjunct Professor of Physics

The National Cancer Institute (NCI)’s Nanotechnology Characterization Laboratory (NCL) is a collaboration among NCI, the National Institute of Science and Technology (NIST), and the Food and Drug Administration (FDA) which aims to facilitate the translation of nanomedicine products to clinics.
 
At the NCL, Jennifer was part of a team of scientists responsible for testing more than 400 candidate nanotech drugs and diagnostics, evaluating safety and efficacy, and assisting with product development from discovery-level work, through scale-up, into clinical trials. NCL has assisted in the development of several nanotech cancer products which are now in clinics, including those from CytImmune Sciences, Nanospectra Biosciences, BIND Therapeutics, and Azaya Therapeutics. 

In addition to the free “Assay Cascade” testing service, NCL conducts industry-funded R&D for discovery work (e.g. formulation, optimizing conjugation chemistries, targeting agents, surface coatings, methods development, etc.). NCL also characterizes nanomaterials for non-oncology applications through contract.
 
Jennifer served as the NCL's scientific lead for alliance, project, and data management. She has established and managed productive collaborations within NCI, FDA, NIST and a network of over 100 drug development labs in industry and academia. She analyzes preclinical data on nanomaterial cancer therapeutics and has contributed to development of analytical/bioanalytical and physicochemical characterization methods and links to in vivo drug performance. Her areas of expertise include nuclear magnetic resonance (NMR) of proteins and nanoparticles, and biophysical modeling of nanoparticle structures and interactions. Jennifer has experience in a variety of issues related to nanotech drug development and regulation and is a member of several working groups related to nano-bioinformatics, nanomedicine, and other nanotechnology issues.

Jennifer Grossman